CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

Robert Izquierdo, The Motley Fool

Sun, May 31, 2026 astatine 11:31 AM CDT 6 min read

Gene-editing exertion has moved from subject fabrication to objective reality, forcing investors to take betwixt commercialized leaders and early-stage innovators. Deciding betwixt CRISPR Therapeutics AG (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) requires weighing existent income against semipermanent potential.

CRISPR Therapeutics focuses connected high-profile hemoglobinopathy treatments done a large partnership, portion Editas is strategically targeting successful vivo cistron editing. Both correspond the cutting borderline of genomic medicine, but they connection vastly antithetic fiscal profiles and hazard levels for idiosyncratic investors successful 2026.

The lawsuit for CRISPR Therapeutics

CRISPR Therapeutics is simply a gene-editing biopharmaceutical institution focused connected processing transformative medicines similar CASGEVY for sickle compartment disease. It serves markets successful hemoglobinopathies and oncology portion centering its probe and improvement operations successful Massachusetts. Because Vertex Pharmaceuticals handles each commercialization activities for CASGEVY, the company's gross is wholly tied to this azygous partner. Customer attraction similar this adds a furniture of hazard to the business.

In its 2025 fiscal year, gross generated from grants totaled $3.5 million, compared to the $35 cardinal successful upfront payments provided by Vertex successful the anterior year. This contributed to a nett nonaccomplishment of $581.6 million, and the institution reported a nett borderline of antagonistic 16,570% for the period. The year-over-year inclination reflects the modulation toward commercializing its pb therapy alternatively than relying connected one-time milestone payments.

As of the December 2025 equilibrium sheet, the debt-to-equity ratio was astir 0.2x. This ratio compares full indebtedness to the worth of shareholder equity, indicating a blimpish magnitude of leverage. The existent ratio, which measures a company's quality to screen short-term debts with assets similar cash, was astir 13.3x. Free currency travel for the twelvemonth was antagonistic $345.9 million, representing the currency burned to enactment ongoing probe and commercialization.

The lawsuit for Editas Medicine

Editas Medicine is focused connected translating CRISPR exertion into successful vivo medicines, which are therapies delivered straight into the patient's body. The institution operates wrong the marketplace for biotech stocks and relies connected collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals for funding. Because these licenses correspond its lone committed imaginable root of funds, this precocious attraction of gross sources increases hazard for investors.